Synairgen PLC
LSE:SNG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Synairgen PLC
Revenue
Synairgen PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Synairgen PLC
LSE:SNG
|
Revenue
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£400m
|
CAGR 3-Years
41%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Revenue
£672m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Revenue
£168.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
27%
|
|
|
Niox Group PLC
LSE:NIOX
|
Revenue
£48.7m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
16%
|
|
Synairgen PLC
Glance View
Synairgen Plc is a holding company, which engages in the provision of respiratory drug discovery and development. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The firm is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The firm is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The firm offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.
See Also
What is Synairgen PLC's Revenue?
Revenue
0
GBP
Based on the financial report for Jun 30, 2024, Synairgen PLC's Revenue amounts to 0 GBP.
